Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-13) + Yahoo Finance
Auditor: Ernst & Young LLP — Clean opinion (2 critical audit matters: sales deductions, unrecognized tax benefits)
One-line verdict: Amgen's F grade reflects the structural reality of a company that leveraged its balance sheet to the hilt with the $27.8 billion Horizon Therapeutics acquisition, leaving $54.6B in debt against only $8.7B in equity. Three screening checks fail outright — DSO surged 21 days, cash covers only 17% of debt, and goodwill plus intangibles equal 473% of equity. However, the M-Score at -2.26 passes cleanly and operating cash flow of $10.0B comfortably supports the debt service. This is a balance sheet risk story, not an earnings manipulation story — but the magnitude of that balance sheet risk demands the F grade.
| Metric | Result |
|---|---|
| Red Flags | **3** (DSO surge, cash vs debt, goodwill/intangibles) |
| Watch Items | **4** (AR growth, CapEx growth, gross margin swing, soft asset growth) |
| Checks Completed | **17/18** |
| Beneish M-Score | **-2.26** (safe zone) |
| Auditor | Ernst & Young — Unqualified opinion |
The Biotech Giant's Post-Acquisition Profile
Amgen is one of the world's leading independent biotechnology companies. In FY2025, the company generated $36.8B in total revenue, up 10% from $33.4B in FY2024. The revenue growth was driven by a diversified portfolio of 14+ principal products.
From the 10-K: "Total product sales increased 10% in 2025, driven by volume growth of 13%, partially offset by declines in net selling price of 3%."
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Revenue | $26.3B | $28.2B | $33.4B | $36.8B | +10% |
| Net Income | $6.6B | $6.7B | $4.1B | $7.7B | +89% |
| Operating Income | — | $7.9B | $7.3B | $9.1B | +25% |
| Gross Margin | 75.7% | 70.0% | 61.5% | 67.2% | +5.7pp |
| Net Margin | 24.9% | 23.8% | 12.2% | 21.0% | +8.7pp |
| ROE | 179% | 108% | 70% | 89% | Volatile |
The dramatic swings require context: FY2024's depressed net income ($4.1B vs $6.7B in FY2023) reflected $12.9B in cost of sales (inflated by Horizon acquisition-related inventory step-ups) and higher interest expense from acquisition debt. FY2025 saw a normalization as those one-time costs faded.
Product Revenue: Diversified but Concentrated
From the 10-K, top products by FY2025 revenue:
| Product | FY2025 | FY2024 | Growth | Indication |
|---|---|---|---|---|
| Prolia | $4.4B | $4.4B | +1% | Osteoporosis |
| Repatha | $3.0B | $2.2B | +36% | Cholesterol |
| Otezla | $2.3B | $2.1B | +7% | Psoriasis |
| ENBREL | $2.2B | $3.3B | -33% | Autoimmune |
| EVENITY | $2.1B | $1.6B | +34% | Osteoporosis |
| XGEVA | $2.1B | $2.2B | -6% | Bone disease |
| TEPEZZA | $1.9B | $1.9B | +3% | Thyroid eye disease |
ENBREL's 33% decline is the most notable trend — facing intense biosimilar and competing therapy pressure. The 10-K lists HUMIRA biosimilars, RINVOQ, and Cosentyx as direct competitors. This is partially offset by strong growth from Repatha (+36%) and EVENITY (+34%).
Three wholesale distributors account for 77% of total gross revenues: McKesson (34%), Cencora (24%), and Cardinal Health (19%).
The $27.8 Billion Horizon Hangover
The dominant balance sheet feature is the Horizon Therapeutics acquisition completed October 6, 2023. From the 10-K: Amgen acquired "all of the outstanding shares of Horizon for $116.50 per share in cash, representing a total consideration of approximately $27.8 billion."
The purchase price allocation from the 10-K:
| Item | Amount |
|---|---|
| Finite-lived intangible assets (developed technology) | $19.6B |
| Goodwill | $3.1B |
| IPR&D | $1.1B |
| Inventories | $5.0B |
| Deferred tax liability | $(2.5B) |
| Other net assets | $(2.5B) |
| **Total** | **$27.8B** |
This acquisition explains the balance sheet distortion. As of December 31, 2025:
| Balance Sheet | FY2025 | FY2024 |
|---|---|---|
| Cash | $9.1B | $12.0B |
| Total Assets | $90.6B | $91.8B |
| Intangible Assets, Net | $22.3B | $27.7B |
| Goodwill | $18.7B | $18.6B |
| Long-term Debt | $50.0B | $56.5B |
| Current Debt | $4.6B | $3.6B |
| Total Equity | $8.7B | $5.9B |
The positive news: Amgen is aggressively paying down debt. From the 10-K: "In 2025, debt repayments totaled $5.0 billion" and "we repurchased an aggregate principal amount of our debt of $1.0 billion... which resulted in a $264 million gain on extinguishment of debt." Total debt declined from $60.1B to $54.6B year-over-year.
Cash Flow: The Saving Grace
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $8.5B | $11.5B | $10.0B |
| CapEx | $(1.1B) | $(1.1B) | $(1.9B) |
| Free Cash Flow | $7.4B | $10.4B | $8.1B |
| CFFO / Net Income | 1.26 | 2.81 | 1.29 |
| Dividends Paid | — | — | ~$5.1B |
From the 10-K: "Cash flows from operating activities in 2025 totaled $10.0 billion, which supported investment in our business, including capital expenditures of $1.9 billion to enhance and expand our manufacturing network, and allowed us to both reduce our debt and return capital to shareholders through the payment of cash dividends."
The CFFO/NI ratio of 1.29 is healthy — earnings are well-backed by cash. The company is prioritizing debt reduction over buybacks: $6.0B in debt retired plus dividends paid, with no share repurchases noted.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO | Fail | DSO surged by 21 days (74 to 95) |
| A2 | AR vs Revenue | Watch | AR growth 41.1% exceeds revenue growth 10.0% |
| A3 | Revenue vs CFFO | Pass | Revenue +10%, CFFO -13%. Cash follows revenue |
A1/A2: DSO surging 21 days is a major flag. Trade receivables grew from $6.8B to $9.6B while revenue grew only 10%. This 41% AR increase is the most concerning single metric. EY flagged sales deductions as a critical audit matter: "As of December 31, 2025, the Company recorded accrued sales deductions of $10.6 billion." The complexity of rebates, chargebacks, and Medicaid discounts creates estimation risk. The DSO surge could reflect timing of large government program settlements or simply that revenue is being recognized faster than cash arrives.
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory | Pass | Inventory -11% vs COGS -6.4%. Normal |
| B2 | CapEx | Watch | CapEx growth 69.5% is >2x revenue growth 10% |
| B3 | SG&A Ratio | Pass | SG&A/Gross Profit = 28.5%, excellent |
| B4 | Gross Margin | Watch | Gross margin swung +5.7pp (61.5% to 67.2%) |
B2: CapEx surged from $1.1B to $1.9B — the 10-K attributes this to "capital expenditures of $1.9 billion to enhance and expand our manufacturing network," including state-of-the-art facilities in Ohio, North Carolina, and Puerto Rico. B4: The 5.7pp gross margin swing reflects the normalization after Horizon acquisition inventory step-ups inflated FY2024 COGS. This is a one-time catch-up, not a structural shift.
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs NI | Pass | CFFO/NI = 1.29. Profits backed by cash |
| C2 | FCF | Pass | FCF $8.1B, FCF/NI = 1.05 |
| C3 | Accruals | Pass | Accruals ratio -2.5%. Low |
| C4 | Cash vs Debt | Fail | Cash $9.1B covers only 17% of debt $54.6B |
C4: This is the heart of the risk. $54.6B in debt against $9.1B cash means a 17% coverage ratio. However, context matters: Debt/EBITDA is 3.2x (acceptable for a pharma company), and Amgen retired $6.0B in debt in FY2025 alone. At current FCF of $8.1B, the company can service the debt — but it leaves minimal margin for error if a key product faces unexpected competition or regulatory setback.
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | Fail | $41.0B = 473% of equity |
| D2 | Leverage | Pass | Debt/EBITDA = 3.2x. Healthy |
| D3 | Soft Asset Growth | Watch | Other assets grew 27.5% vs revenue 10% |
| D4 | Impairment | N/A | No write-off data |
D1: $41.0B in goodwill and intangibles representing 473% of equity is extreme. Goodwill of $18.7B is entirely from acquisitions (primarily Horizon at $3.1B, plus legacy deals). Intangible assets of $22.3B are finite-lived developed-product-technology rights that amortize as products age. The intangibles declined from $27.7B to $22.3B — a $5.4B reduction in one year — indicating healthy amortization. Goodwill was stable (no impairment recognized in FY2025).
M&A Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Post-Acquisition FCF | Pass | FCF after acquisitions positive |
| E2 | Goodwill Surge | Pass | Goodwill+Intangibles change -12% YoY |
Beneish M-Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | M-Score | Pass | -2.26 (< -2.22). Unlikely manipulator |
The M-Score of -2.26 sits just below the -2.22 threshold, placing Amgen in the safe zone. The DSRI component of 1.283 (driven by the AR surge) is the highest individual contributor, but it alone does not push the score into manipulation territory.
Key Risks from Item 1A
1. Biosimilar and generic competition is accelerating. The 10-K provides an exhaustive competitor table for every major product. ENBREL already declined 33% in FY2025. Prolia faces "denosumab biosimilars" from "various" competitors. The 10-K warns: "We currently face competition from biosimilars and generics and expect to face increasing competition from biosimilars and generics in the future."
2. Drug pricing pressure is structural. The IRA's Medicare price negotiation mechanism is impacting the portfolio. The 10-K notes Amgen is "taking actions that satisfy the components outlined in the July MFN Letter, including the Administration's MFN pricing requests," including extending MFN pricing to Medicaid. This represents structural margin compression.
3. Sales deduction estimation risk. The $10.6B in accrued sales deductions is enormous — 30% of gross product revenue. EY flagged this as a critical audit matter because "the estimated sales deductions are based on current contractual and statutory requirements, market events and trends, internal and external historical data, and forecasted customer buying patterns."
4. Unrecognized tax benefits. EY's second critical audit matter: "the Company operates in various jurisdictions in which differing interpretations of complex tax laws and regulations create uncertainty and necessitate the use of significant judgment in the determination of the Company's unrecognized tax benefits."
Altman Z-Score and F-Score
| Model | Score | Interpretation |
|---|---|---|
| Altman Z-Score | **0.34** | Distress zone (<1.81). Bankruptcy risk elevated |
| F-Score (Dechow) | **0.54** | Low fraud probability (0.20%) |
The Z-Score of 0.34 is alarming but requires context. The Altman Z-Score was designed for manufacturing companies and penalizes heavily for high debt-to-equity ratios. Amgen's $54.6B debt against $8.7B equity mathematically produces a distress reading. In reality, the company generates $10B+ in annual operating cash flow and has ample capacity to service its debt. The Z-Score is a valid warning about leverage but not a bankruptcy prediction for a company with Amgen's cash flow profile.
Summary
| # | Check | Result |
|---|---|---|
| A1-A3 | Revenue Quality | Fail-Watch-Pass |
| B1-B4 | Expense Quality | Pass-Watch-Pass-Watch |
| C1-C4 | Cash Flow Quality | Pass-Pass-Pass-Fail |
| D1-D4 | Balance Sheet | Fail-Pass-Watch-N/A |
| E1-E2 | M&A Risk | Pass-Pass |
| F1 | Beneish M-Score | Pass |
Grade: F. The balance sheet is dangerously leveraged, but the operating business is healthy.
The F grade is driven by three structural issues, all traceable to the Horizon acquisition:
The mitigating factors are real: M-Score passes cleanly (-2.26), CFFO/NI is 1.29, free cash flow is $8.1B, Debt/EBITDA is 3.2x, and the company repaid $6.0B in debt in FY2025. The risk is not earnings manipulation — it is balance sheet fragility. If a major product faces unexpected loss of exclusivity or a clinical trial fails for a key pipeline asset, the debt burden leaves little room for error.
**Disclaimer**: This report is based on Amgen's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.
Data: SEC EDGAR 10-K (Filed 2026-02-13) + Yahoo Finance
Auditor: Ernst & Young LLP (Unqualified opinion, 2 critical audit matters)